Renflexis is paid 14.1% below Remicade
3 biosimilars bill against Remicade (J1745). On average they are paid ↓ 0.9% relative to the reference product per 10 MG in 4Q26.
- Remicade (reference)
- Renflexis
- Inflectra
- Avsola
AfliberceptBevacizumabDenosumabEculizumabEpoetin alfaFilgrastimInfliximabNatalizumabPegfilgrastimRanibizumabRituximabTocilizumabTrastuzumabUstekinumab
All products
| Product | Code | CMS description | Per 10 MG | vs. reference | CMS 8% add-on note | 8 quarters |
|---|---|---|---|---|---|---|
| Remicade | J1745 | Infliximab not biosimil 10mg | $29.856 | Reference | – | |
| Renflexis | Q5104 | Injection, renflexis | $25.649 | ↓ 14.1% | Yes | |
| Inflectra | Q5103 | Injection, inflectra | $28.456 | ↓ 4.7% | Yes | |
| Avsola | Q5121 | Inj. avsola, 10 mg | $34.686 | ↑ 16.2% | No |
Payment limits are from the CMS 4Q26 file. Which products are grouped together comes from the site’s biosimilar groups list (reference/biosimilar_groups/2026-10-17T183707Z_d3109bb50c53.csv), checked by hand; it is not a CMS file. “CMS 8% add-on note” shows whether CMS’s notes say the 8% of reference product add-on was applied.